Follicular lymphoma (FL) is the most common form of low grade or slow-growing non-Hodgkin’s lymphoma (NHL). There are approximately 56,000 new cases of non-Hodgkin’s lymphoma (NHL) per year, with approximately 40% being indolent lymphomas such as follicular lymphoma (FL) and approximately 60% being the more aggressive lymphomas such as diffuse large B cell lymphoma (DLBCL) type. Treatments of varying efficacy exist for FL and DLBCL; however, due to the wide variety of subtypes of this disease, a frontline approach is lacking. FL can arise anywhere in the body within the germinal centers of the lymph nodes. Between 40 to 80 percent of patients will respond to initial therapy, but virtually all will relapse. Ten percent of the relapsed patients will not respond to treatment at all (refractory).
BP1002 (Liposomal Bcl-2) is a neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of Bcl-2, a protein involved in regulating programmed cell death. Bcl-2 is overexpressed in more than 90 percent of FL and in a wide variety of solid tumors. Amplified expression of Bcl-2 protein in FL is due to the defining genetic hallmark of the disease, the chromosomal translocation t(14;18), which moves the Bcl-2 gene from chromosome 18 into the heavy chain immunoglobin locus on chromosome 14. Overexpression of Bcl-2 stops affected cells from being killed by chemotherapy. We believe that BP1002 overcomes the failures of previous attempts at inhibiting Bcl-2 by specifically interrupting the protein expression of one protein and not a family of necessary proteins and does so without inherent toxicity. With BP1002, more drug substance can reach the circulating lymphocytes so that the cancer cells can be treated with a therapeutically relevant dose. We believe BP1002 provides a new tool for cancer treatment for not just lymphomas, but also many cancers for which Bcl-2 expression is preventing cell death. The introduction of a new, non-toxic, and specific Bcl-2 inhibitor could be a major advance in cancer therapeutics.
Bio-Path is preparing to submit an IND for BP1002 and is planning to initiate a Phase 1 clinical trial for lymphoma in 2018
Prexigebersen (Liposomal Grb2 antisense) is Bio-Path’s lead product candidate, a neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2).Learn More